Regenerative Medicine & Fibrosis Group, Institute for Liver & Digestive Health, University College London, Royal Free Hospital, London, UK.
First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.
Inflamm Bowel Dis. 2019 Oct 18;25(11):1740-1750. doi: 10.1093/ibd/izz115.
The current methodologies for the identification of therapeutic targets for inflammatory bowel disease (IBD) are limited to conventional 2-dimensional (2D) cell cultures and animal models. The use of 3D decellularized human intestinal scaffolds obtained from surgically resected intestine and engineered with human intestinal cells may provide a major advancement in the development of innovative intestinal disease models. The aim of the present study was to design and validate a decellularization protocol for the production of acellular 3D extracellular matrix (ECM) scaffolds from the human duodenum.
Scaffolds were characterized by verifying the preservation of the ECM protein composition and 3D architecture of the native intestine and were employed for tissue engineering with primary human intestinal myofibroblasts for up to 14 days.
Engrafted cells showed the ability to grow and remodel the surrounding ECM. mRNA expression of key genes involved in ECM turnover was significantly different when comparing primary human intestinal myofibroblasts cultured in 3D scaffolds with those cultured in standard 2D cultures on plastic dishes. Moreover, incubation with key profibrogenic growth factors such as TGFβ1 and PDGF-BB resulted in markedly different effects in standard 2D vs 3D cultures, further emphasizing the importance of using 3D cell cultures.
These results confirm the feasibility of 3D culture of human intestinal myofibroblasts in intestinal ECM scaffolds as an innovative platform for disease modeling, biomarker discovery, and drug testing in intestinal fibrosis.
目前用于鉴定炎症性肠病(IBD)治疗靶点的方法仅限于传统的二维(2D)细胞培养和动物模型。使用从手术切除的肠中获得的、经人肠细胞工程化的 3D 脱细胞人肠支架可能会在开发创新的肠道疾病模型方面取得重大进展。本研究旨在设计并验证一种从人十二指肠制备无细胞 3D 细胞外基质(ECM)支架的脱细胞方案。
通过验证保留 ECM 蛋白组成和天然肠的 3D 结构来对支架进行表征,并将其用于原代人肠成肌纤维细胞的组织工程,培养时间长达 14 天。
植入的细胞显示出生长和重塑周围 ECM 的能力。与在塑料培养皿上的标准 2D 培养相比,比较在 3D 支架中培养的原代人肠成肌纤维细胞,关键基因在 ECM 周转中的 mRNA 表达明显不同。此外,孵育关键的促纤维化生长因子,如 TGFβ1 和 PDGF-BB,在标准 2D 与 3D 培养中会产生明显不同的效果,进一步强调了使用 3D 细胞培养的重要性。
这些结果证实了在肠 ECM 支架中进行人肠成肌纤维细胞的 3D 培养作为疾病建模、生物标志物发现和肠纤维化药物测试的创新平台的可行性。